Activation of Voltage-Gated KCNQ/Kv7 Channels by Anticonvulsant Retigabine Attenuates Mechanical Allodynia of Inflammatory Temporomandibular Joint in Rats
Open Access
- 1 January 2010
- journal article
- Published by SAGE Publications in Molecular Pain
- Vol. 6, 49
Abstract
Background: Temporomandibular disorders (TMDs) are characterized by persistent orofacial pain and have diverse etiologic factors that are not well understood. It is thought that central sensitization leads to neuronal hyperexcitability and contributes to hyperalgesia and spontaneous pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) are currently the first choice of drug to relieve TMD pain. NSAIDS were shown to exhibit anticonvulsant properties and suppress cortical neuron activities by enhancing neuronal voltage-gated potassium KCNQ/Kv7 channels (M-current), suggesting that specific activation of M-current might be beneficial for TMD pain. Results: In this study, we selected a new anticonvulsant drug retigabine that specifically activates M-current, and investigated the effect of retigabine on inflammation of the temporomandibular joint (TMJ) induced by complete Freund's adjuvant (CFA) in rats. The results show that the head withdrawal threshold for escape from mechanical stimulation applied to facial skin over the TMJ in inflamed rats was significantly lower than that in control rats. Administration of centrally acting M-channel opener retigabine (2.5 and 7.5 mg/kg) can dose-dependently raise the head withdrawal threshold of mechanical allodynia, and this analgesic effect can be reversed by the specific KCNQ channel blocker XE991 (3 mg/kg). Food intake is known to be negatively associated with TMJ inflammation. Food intake was increased significantly by the administration of retigabine (2.5 and 7.5 mg/kg), and this effect was reversed by XE991 (3 mg/kg). Furthermore, intracerebralventricular injection of retigabine further confirmed the analgesic effect of central retigabine on inflammatory TMJ. Conclusions: Our findings indicate that central sensitization is involved in inflammatory TMJ pain and pharmacological intervention for controlling central hyperexcitability by activation of neuronal KCNQ/M-channels may have therapeutic potential for TMDs.Keywords
This publication has 48 references indexed in Scilit:
- NeuralKCNQ(Kv7) channelsBritish Journal of Pharmacology, 2009
- Diclofenac sodium and occlusal splint therapy in TMJ osteoarthritis: a randomized controlled trialJournal of Oral Rehabilitation, 2008
- Retigabine reduces the excitability of unmyelinated peripheral human axonsNeuropharmacology, 2008
- Kv7.2–7.5 voltage-gated potassium channel (KCNQ2–5) opener, retigabine, reduces capsaicin-induced visceral pain in miceNeuroscience Letters, 2007
- Analgesic action of gabapentin on chronic pain in the masticatory muscles: A randomized controlled trialPain, 2007
- Inflammatory cell and cytokine patterns in patients with chronic polyarthritis and temporomandibular joint involvementActa Odontologica Scandinavica, 2006
- Estrogenic effect on swelling and monocytic receptor expression in an arthritic temporomandibular joint modelThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- The contribution of neuroimaging techniques to the understanding of supraspinal pain circuits: Implications for orofacial painOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2005
- Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cellsBritish Journal of Pharmacology, 2001
- Meal Pattern Analysis in Response to Temporomandibular Joint Inflammation in the RatJournal of Dental Research, 2000